Marghalani Siham, Alghamdi Yara, Albrakati Bakr A, Huwait Hassan F, Mohanna Abdulrahman T
Dermatology, King Abdulaziz Medical City (KAMC), Jeddah, SAU.
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU.
Cureus. 2024 Mar 17;16(3):e56310. doi: 10.7759/cureus.56310. eCollection 2024 Mar.
The coronavirus disease 2019 (COVID-19) infection has led to accelerated development and utilization of vaccines to prevent its implications on health. One of these vaccines is a vector-based, Oxford-AstraZeneca Vaccine (AZD1222). Frequently reported side effects are related to host-immune response. While dermatologic manifestation is peculiar in nature and denotes a serious eruption that might defer future vaccination. Herein, we present a case of a medically free 37-year-old female who developed clinical and histological evidence of pityriasis rosea (PR) after administration of a second-dose vaccination of AZD1222. The first dose of vaccination was administered as Pfizer BioNTech COVID-19 mRNA (BNT162b2) vaccine. This case is unique in nature as this patient developed AZD1222-induced PR, while some reports in the literature have linked PR to the BNT162b2 vaccine. This patient continued to receive a booster vaccination with BNT162b2 with no reportable side effects.
2019年冠状病毒病（COVID-19）感染促使人们加速研发和使用疫苗，以预防其对健康的影响。其中一种疫苗是基于载体的牛津-阿斯利康疫苗（AZD1222）。常见的副作用与宿主免疫反应有关。虽然皮肤表现较为特殊，意味着可能会推迟未来接种疫苗的严重皮疹。在此，我们报告一例37岁无基础疾病的女性，在接种第二剂AZD1222疫苗后出现了玫瑰糠疹（PR）的临床和组织学证据。第一剂疫苗接种的是辉瑞BioNTech COVID-19 mRNA（BNT162b2）疫苗。该病例较为独特，因为该患者出现了AZD1222诱导的PR，而文献中的一些报道将PR与BNT162b2疫苗联系起来。该患者继续接种了BNT162b2加强针，未出现可报告的副作用。
